Official websites use. Share sensitive information only on official, secure websites. This work is published and licensed by Dove Medical Press Limited. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
For permission for commercial use of this work, please see paragraphs 4. In prisons in England, integrated treatment for opioid use disorder OUD is accessible and effective, commonly based on daily supervised consumption of methadone. Treatment limitations inadequate dosing, nonengagement with care, stigma, diversion and bullying are noted.
Flexible dose, injectable prolonged-release buprenorphine PRB which removes the need for daily dispensing and supervision is suggested for prisoner care. This work aimed to predict the difference in costs of current standard of care vs partial introduction of PRB.
Evidence describing costs to deliver OUD care for prisoners pharmacotherapy, direct service, indirect health care, indirect security costs were collected, including assumptions describing how care would be delivered. Evidence sources include national data sources, scientific literature and from experience in the prison health care setting.
For a representative standard prison population requiring OUD care of prisoners in England PRB introduction is associated with a predicted reduction in direct and indirect costs of OUD care.
